Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Biochemical Markers, Genotype, and Inflammation in Pediatric Inflammatory Bowel Disease: A Danish Population-Based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Biological treatment of Crohn's disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term, clinical follow-up in fatty liver patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Insulin-like growth factor 1 and growth hormone in chronic liver disease.

    Publikation: Bidrag til tidsskriftReviewForskning

  5. Sex, sex hormones and chronic liver diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Intrahepatic cholangiocarcinoma (iCCA) comprises one of the most rapidly evolving cancer types. An underlying chronic inflammatory liver disease that precedes liver cancer development for several decades and creates a pro-oncogenic microenvironment frequently impairs progress in therapeutic approaches. Depending on the cellular target of malignant transformation, a large spectrum of molecular and morphological patterns is observed. As such, it is crucial to advance our existing understanding of the molecular pathogenesis of iCCA, particularly its genomic heterogeneity, to improve current clinical strategies and patient outcome. This was achieved for other cancers, such as breast carcinoma, facilitated by the delineation of patient subsets and of precision therapies. In iCCA, many questions persevere as to the evolutionary process and cellular origin of the initial transforming event, the context of tumor plasticity and the causative features driving the disease. Molecular profiling and pathological techniques have begun to underline persistent alterations that may trigger inherited drug resistance (a hallmark of hepatobiliary and pancreatic cancers), metastasis and disease recurrence. In this review, we will focus on the key molecular achievements that are currently advancing the characterization and stratification of iCCA. We will discuss current clinical practice and how genomic achievements may advance diagnosis and therapy as well as ultimately improve patient outcome.

OriginalsprogEngelsk
TidsskriftDigestive diseases (Basel, Switzerland)
Vol/bind34
Udgave nummer4
Sider (fra-til)440-51
Antal sider12
ISSN0257-2753
DOI
StatusUdgivet - 14 maj 2016

ID: 49784667